Article, News
Prescient to announce Phase 1b cancer trial results at world’s largest haematology conference
Prescient Therapeutics (ASX:PTX) has announced that its abstract for the results of a Phase 1b study in T-cell lymphomas has been accepted for poster presentation…
Article, News
Prescient Therapeutics to present clinical data at prestigious US conference
Results of a Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) Phase 1b study in T cell lymphomas have been accepted for poster presentation at the prestigious American Society of Hematology…
Article, News
Why are clinical advances by this small-cap ASX biotech in FY23 so significant?
Prescient Therapeutics Limited (ASX: PTX) has been witnessing significant achievements and progress towards its goal of developing targeted cancer treatments. In the latest financial year…
Article, News
Prescient Therapeutics prepares for ‘pivotal’ year of PTX-100 development to treat T-cell lymphomas
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has reported a solid end to financial year 2023 which it says has set the stage for a pivotal…
Article, News
‘Above and beyond approved therapies’: How Prescient Therapeutics is at the forefront of cancer fighting
Prescient Therapeutics is on a mission to improve outcomes for cancer patients, and it is making progress with a diverse portfolio of later and early-stage…
Article, News
Prescient Therapeutics (ASX:PTX) – TechKnow Invest Roadshow, August 2023
Steven Yatomi Clarke – CEO and Managing Director – Prescient Therapeutics (ASX:PTX) is a clinical-stage biotech company developing personalised medicine approaches to cancer, including targeted…
Article, News
Strong quarter for Prescient bolsters future of further trials
Clinical stage oncology company Prescient Therapeutics Ltd (ASX: PTX) has finished off another strong quarter with a healthy $21.8 million cash balance that will serve…
Article, News
TechKnow Invest Roadshow
Hear Prescient Therapeutics (ASX: PTX) CEO and Managing Director Steven Yatomi-Clarke present at the TechKnow Invest Roadshow – Gold Coast.
Article, News
ASX Quarterly Wrap: Dimerix sees strong kidney drug trial recruitment, Prescient advances cancer therapy
It’s the quarterly season again as the ASX market announcements page becomes increasingly flooded with update lodgements. To save you the trouble of trudging through…
Article, News
Health Kick Podcast: Prescient Therapeutics an emerging global leader in the next generation of personalised cancer therapies.
Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast. …
RECENT POSTS
Categories
- Article (102)
- Media (6)
- News (295)
- Uncategorized (1)
- Webcast Video (7)